Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASP Isotopes Inc.ASPI · Entity 5371 | Director | November 12, 2025 | April 18, 2026 |
| Allarity Therapeutics, Inc.ALLR · Entity 7594 | Director | December 20, 2021 | December 22, 2021 |
| GH Research PLCGHRS · Entity 4545 | Director | August 11, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASP Isotopes Inc.
Report date November 12, 2025 · Filed April 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,044,928 |
Ending reported balance
After 2026-04-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-11-12 · Grant · Acquired 25,469 · Balance 1,020,022 F1: Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee. Row 2 · 2025-12-18 · Grant · Acquired 36,548 · Balance 1,056,570 F2: 2025 annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. Row 3 · 2026-04-16 · Sale · Disposed 11,642 · Balance 1,044,928 F3: The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025 and includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award pursuant to an issuer equity incentive plan. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.055 to $5.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee.
F2: 2025 annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc.
F3: The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025 and includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award pursuant to an issuer equity incentive plan.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.055 to $5.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2.
Allarity Therapeutics, Inc.
Report date December 20, 2021 · Filed December 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001SEC Table I · non-derivative | Direct | 22,672 |
Reported balance
Holding disclosure · report date 2021-12-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 22,672 F1: On December 20, 2021 (the "Closing Date"), Allarity Therapeutics, Inc., a Delaware corporation (the "Issuer") completed the recapitalization share exchange (the "Closing") pursuant to which the Issuer's wholly owned Delaware subsidiary acquired the asset and assumed the liability of assumption of Allarity Therapeutics A/S ("Allarity A/S") in exchange for the Common Stock of the Issuer ("Recapitalization Share Exchange") as described in the Issuer's Registration Statement on Form S-4 (File No. 333-258968 )(the "Registration Statement"). As a result of the Closing, holders of each outstanding ordinary share of Allarity A/S has a right to 0.02 shares of Issuer's Common Stock for each Allarity A/S ordinary share issued and outstanding (the "Exchange Ratio") to the holder. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.11 · Expires 2026-11-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The Reporting Person was originally granted compensatory warrants ("Compensatory Option") by Allarity A/S conferring a right to purchase ordinary shares of Allarity A/S (the "Options"). Upon the Closing, each Compensatory Option converted into an option to purchase a number of shares of Common Stock of Issuer equal to the product (rounded down to the nearest whole number) of (a) the number of ordinary shares of Allarity A/S subject to such Compensatory Option immediately prior to the effective time multiplied by (b) the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to (i) the exercise price per share of such Compensatory Warrant immediately prior to the effective time divided by (ii) the Exchange Ratio and converted into U.S. dollars, as further described in the Registration Statement. The exercise price in dollars is based on the exchange rate of 1 USD = 9.15354 SEK which was the exchange rate reported on December 20, 2021 the date of Closing. The exercise price and the number of shares of common stock underlying the stock option reflects the Exchange Ratio adjustment made in connection with the Closing. F3: The stock option vested with respect to 25% of the shares on November 24, 2021, with 75% vesting 1/36 per month monthly thereafter, subject to the Reporting Person's continued service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 20, 2021 (the "Closing Date"), Allarity Therapeutics, Inc., a Delaware corporation (the "Issuer") completed the recapitalization share exchange (the "Closing") pursuant to which the Issuer's wholly owned Delaware subsidiary acquired the asset and assumed the liability of assumption of Allarity Therapeutics A/S ("Allarity A/S") in exchange for the Common Stock of the Issuer ("Recapitalization Share Exchange") as described in the Issuer's Registration Statement on Form S-4 (File No. 333-258968 )(the "Registration Statement"). As a result of the Closing, holders of each outstanding ordinary share of Allarity A/S has a right to 0.02 shares of Issuer's Common Stock for each Allarity A/S ordinary share issued and outstanding (the "Exchange Ratio") to the holder.
F2: The Reporting Person was originally granted compensatory warrants ("Compensatory Option") by Allarity A/S conferring a right to purchase ordinary shares of Allarity A/S (the "Options"). Upon the Closing, each Compensatory Option converted into an option to purchase a number of shares of Common Stock of Issuer equal to the product (rounded down to the nearest whole number) of (a) the number of ordinary shares of Allarity A/S subject to such Compensatory Option immediately prior to the effective time multiplied by (b) the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to (i) the exercise price per share of such Compensatory Warrant immediately prior to the effective time divided by (ii) the Exchange Ratio and converted into U.S. dollars, as further described in the Registration Statement. The exercise price in dollars is based on the exchange rate of 1 USD = 9.15354 SEK which was the exchange rate reported on December 20, 2021 the date of Closing. The exercise price and the number of shares of common stock underlying the stock option reflects the Exchange Ratio adjustment made in connection with the Closing.
F3: The stock option vested with respect to 25% of the shares on November 24, 2021, with 75% vesting 1/36 per month monthly thereafter, subject to the Reporting Person's continued service as of each vesting date.
GH Research PLC
Report date August 11, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2033-08-11 | Direct | 2,202 |
Reported balance
After 2026-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-11 · Grant · Acquired 2,202 · Balance 2,202 F1: The share options are immediately fully vested, but are not exercisable until August 11, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The share options are immediately fully vested, but are not exercisable until August 11, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 13, 2026 20:59 UTC | GH Research PLC GHRS · Entity 4545 | GrantShare Options (Right to Buy) · Derivative | 2,202 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032856 · form4.xml · derivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,202 Underlying: Ordinary Shares · 2,202 shares Expires 2033-08-11 F1 · derivative.exercise_date: The share options are immediately fully vested, but are not exercisable until August 11, 2028. Read SEC document |
| April 16, 2026 Filed Apr 18, 2026 01:54 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 11,642 | $5.21 | $60,596.61 |
DisclosureSEC source: 0001477932-26-002387 · form4.xml · nonDerivative · entry 3 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,044,928 F3 · kind: The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025 and includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award pursuant to an issuer equity incentive plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.055 to $5.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| December 18, 2025 Filed Apr 18, 2026 01:54 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 36,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002387 · form4.xml · nonDerivative · entry 2 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,056,570 F2 · price: 2025 annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. Read SEC document |
| November 12, 2025 Filed Apr 18, 2026 01:54 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 25,469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002387 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,020,022 F1 · price: Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:40 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 75,000 | $9.28 | $696,232.50 |
DisclosureSEC source: 0001477932-25-006495 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,553 F1 · kind: The sale of shares reported in this Form 4 includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award for 200,000 shares pursuant to an issuer equity incentive plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.95 to $10.20, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 01:58 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 95,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-008021 · form4.xml · nonDerivative · entry 2 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,069,553 F2 · date: Annual award of common stock for service as an independent director of ASP Isotopes Inc. F2 · price: Annual award of common stock for service as an independent director of ASP Isotopes Inc. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 01:58 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 77,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-008021 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 974,315 F1 · date: This award of common stock was issued in lieu of quarterly cash fees payable to the reporting person for service as an independent director of ASP Isotopes Inc. F1 · price: This award of common stock was issued in lieu of quarterly cash fees payable to the reporting person for service as an independent director of ASP Isotopes Inc. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 00:34 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 42,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-007550 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896,689 F1 · date: Annual award of common stock for service as an independent director of ASP Isotopes Inc. F1 · price: Annual award of common stock for service as an independent director of ASP Isotopes Inc. Read SEC document |
| October 26, 2023 Filed Oct 31, 2023 01:51 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 104,167 | $0.96 | $100,000.32 |
DisclosureSEC source: 0001477932-23-007984 · form4.xml · nonDerivative · entry 2 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 854,167 F2 · deemedExecutionDate: Shares of the Issuer's Common Stock were purchased in the Issuer's private placement of Common pursuant to a Securities Purchase Agreement, dated October 9, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock acquired were purchased at a price of $0.96 per share of Common Stock (the consolidated closing bid price per share immediately preceding the signing of the binding agreement to issue the securities). Read SEC document |
| August 10, 2023 Filed Oct 31, 2023 01:51 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007984 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 F1 · deemedExecutionDate: This special one-time equity award of 200,000 restricted shares was made in connection with the appointment of Mr. Moore to the Special Projects Committee of the board of Directors. Mr. Moore will vest in four equal installments every six months. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 11:04 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 50,000 | $0.50 | $24,995.00 |
DisclosureSEC source: 0001477932-23-004971 · form4.xml · nonDerivative · entry 2 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 11:04 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 50,000 | $0.50 | $24,995.00 |
DisclosureSEC source: 0001477932-23-004971 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:05 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 20,000 | $0.31 | $6,230.00 |
DisclosureSEC source: 0001477932-23-003780 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Read SEC document |
| May 10, 2023 Filed May 16, 2023 12:09 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 10,000 | $0.50 | $5,000.00 |
DisclosureSEC source: 0001477932-23-003621 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,000 Read SEC document |
| April 06, 2023 Filed Apr 11, 2023 14:50 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 20,000 | $1.00 | $19,998.00 |
DisclosureSEC source: 0001477932-23-002397 · form4.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,000 Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 17:41 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-073093 · ownership.xml · nonDerivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 F1 · deemedExecutionDate: This special one-time equity award of 200,000 restricted shares was contingent upon the completion of our IPO. Mr. Moore will receive 100,000 restricted shares of our common stock on November 15, 2023 and 100,000 restricted shares of our common stock on November 15, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.